Treatment of chronic hepatitis С (genotype 6) in patients with contraindications to interferon-α
https://doi.org/10.22625/2072-6732-2015-7-4-100-102
About the Authors
D. A. Lioznov
First Saint-Petersburg State Medical University named after academician I.P. Pavlov, Saint-Petersburg, Russia
Science Research Institute of Epidemiology and Microbiology named after Pateur, Saint-Petersburg, Russia
Russian Federation
Russian Federation
N. H. Chung
Science Research Institute of Epidemiology and Microbiology named after Pateur, Saint-Petersburg, Russia
Medical and Pharmacy University, Ho Chi Minh City, Vietnam
Russian Federation
Russian Federation
S. L. Nikolaenko
First Saint-Petersburg State Medical University named after academician I.P. Pavlov, Saint-Petersburg, Russia
North-Western Federal Medical Research Centre named after V.A. Almazov, Saint-Petersburg, Russia
Russian Federation
Russian Federation
References
1. Chao D. T., Abe K., Nguyen M. H. Systematic review: epidemiology of hepatitis C genotype 6 and its management. Alimentary Pharmacology & Therapeutics. 2011, 34: 286–296.
2. Messina J. P., Humphreys I., Flaxman A., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatologyю 2015, 61: 77–87.
3. Pybus O.G., Barnes E., Taggart R., et al. Genetic History of Hepatitis C Virus in East Asia . Journal of Virology. 2009;83(2):1071-1082.
4. EASL. Recommendations on treatment of hepatitis C. April, 2014. (http://files.easl.eu/easl-recommendations-ontreatment-of-hepatitis-c-summary.pdf)
5. EASL. Recommendations on treatment of hepatitis C. July, 2015. (http://www.easl.eu/medias/cpg/HEPC-2015/Summary.pdf)
Review
For citations:
Lioznov D.A., Chung N.H., Nikolaenko S.L. Treatment of chronic hepatitis С (genotype 6) in patients with contraindications to interferon-α. Journal Infectology. 2015;7(4):100-102. (In Russ.) https://doi.org/10.22625/2072-6732-2015-7-4-100-102
Views:
537
.png)
.png)
Email this article 